Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
08:25am, Tuesday, 09'th Nov 2021
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -8.62% and 10.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th
Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings
12:52pm, Friday, 08'th Oct 2021
Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference.
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
New Strong Sell Stocks for September 14th
10:42am, Tuesday, 14'th Sep 2021
ATR, FTAI, HGEN, LMB, and MRSN have been added to the Zacks Rank #5 (Strong Sell) List on September 14, 2021.
Why Are Mersana Therapeutics Shares Trading Lower On Friday?
10:57am, Friday, 10'th Sep 2021
Mersana Therapeutics Inc (NASDAQ: MRSN) stock is moving lower during the market trading session. Investors are reacting to interim data from the ovarian cancer Phase 1 trial evaluating Upifitamab Ril
Mersana Therapeutics to Present at Upcoming Investor Conferences
08:00am, Tuesday, 07'th Sep 2021
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 18'th Aug 2021
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2021 Results - Earnings Call Transcript
02:19pm, Friday, 06'th Aug 2021
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2021 Results - Earnings Call Transcript
Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
06:00am, Friday, 06'th Aug 2021
CAMBRIDGE, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates
08:00am, Friday, 30'th Jul 2021
CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
02:13am, Tuesday, 29'th Jun 2021
Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Mersana Therapeutics, Inc.'s (MRSN) CEO Anna Protopapas on Q1 2021 Results - Earnings Call Transcript
10:54pm, Monday, 10'th May 2021
Mersana Therapeutics, Inc.'s (MRSN) CEO Anna Protopapas on Q1 2021 Results - Earnings Call Transcript
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
06:47pm, Monday, 10'th May 2021
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -28.21% and -95.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the
Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
04:01pm, Monday, 10'th May 2021
- Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer - Ended first quarter of 2021 with $228 million in cash
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates
08:00am, Monday, 03'rd May 2021
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru
